Rentschler Biopharma

US Tariffs Fatal for European Pharma

Trump's tariff policy is a considerable burden and a break with previous practice.

Rentschler Plans New Buffer Media Facility at its Headquarters

In a move to further increase production efficiency and modernize the site, German contract development and manufacturing organization (CDMO) Rentschler Biopharma plans to construct a new buffer media station at its company headquarters in Laupheim. According to Rentschler, this is the largest single investment in the German site.

The Evolution of the CDMO Industry

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.

Expert Statement: Federico Pollano, Rentschler

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

Rentschler in Collaboration to Improve AAV-Manufacturing for Gene Therapies

German CDMO Rentschler Biopharma is collaborating with the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organization specializing in the advancement of cell and gene therapies, and Oxford-based mass photometry specialist Refeyn, to improve the manufacturing adeno-associated viruses (AAVs).

Rentschler Appoints Mark Caswell as Vice President, US Facility Site Head

Rentschler Biopharma has appointed Mark Caswell as Vice President and Site Head. He joined Rentschler in July 2022 and is managing all operations at the company’s US facilities in Milford, MA.

CureVac Cancels two Vaccine Manufacture Deals

German biotech CureVac has canceled manufacturing contracts with two prospective partners for its Covid-19 vaccine CVnCoV while retaining others. The company said on Sept. 14 it would end the arrangements with Germany’s Wacker Chemie and Switzerland’s Celonic Group, but leave the deals with Rentschler Biopharma and Novartis intact.

Rentschler Invests in UK Cell and Gene Therapy Site

German CDMO Rentschler Biopharma is to establish manufacturing capacity for advanced therapy medicinal products (ATMPs), including Adeno-associated virus (AAV) vectors for clinical trials, at the Cell and Gene Therapy Catapult (CGT) site in Stevenage, UK.

Rentschler to Support BioNTech-Pfizer Vaccine

German CDMO Rentschler Biopharma has reached agreement with Pfizer and BioNTech to handle the downstream purification process for the partnership’s mRNA-based COVID-19 vaccine. No price tag was disclosed for the deal that also calls for the CDMO to handle small-batch manufacturing for a range of BioNTech's other mRNA clinical-stage projects.

Facing Strong Headwinds

So far, the pharmaceutical industry — including CMOs/CDMOs — has responded well to the outbreak of the Covid-19 pandemic.

Outsourcing Services: from Gene to Patient

Rentschler Biopharma SE, headquartered in Laupheim, Germany, is a leading, family-owned, full-service biopharma CDMO. Owing to agile decision making and efficient processes, Rentschler Biopharma is the preferred outsourcing partner for bioprocess development, cGMP manufacturing, as well as elaboration of product approval strategies for over 150 clients worldwide.

Nikolaus F. Rentschler and Frank Mathias Awarded as "EY Entrepreneur of the Year"

Driving Innovation and Extending Its Global Reach

Last year, Rentschler Biopharma, a German contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced its "Strategy 2025."

Rentschler Biopharma Extends Japanese Pact

German biopharmaceuticals contract development and manufacturing organization Rentschler Biopharma is extending and deepening its existing collaboration in Japan with Summit Pharmaceuticals International (SPI), a wholly owned subsidiary of Sumitomo.

Rentschler Expands European Manufacturing Capabilities with GE Bioprocess Technologies

GE Healthcare Life Sciences and Rentschler Mark Handover

Rentschler Facility Wins ‘Facility of the Year Award’ 2012 in Equipment Innovation

Pharmaceutical Technology - The new manufacturing facility of German biotech company Rentschler has won the 2012 Facility of the Year Award (FOYA) in the category "Equipment Innovation" for its flexible, multi-product manufacturing facility designed to minimize manufacturing costs and product cycle times.